BioSpace News Archive

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the first quarter ended March 31, 2023.

Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”) today reported its financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Codexis, Inc., a leading enzyme engineering company, announced the unveiling of its Enzyme-Catalyzed Oligonucleotide Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA oligonucleotide therapeutics at scale.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company) a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, today reported first quarter 2023 financial results and provided operational highlights.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly investor conference call previously scheduled for Thursday, May 11, 2023 at 4:30pm ET to Tuesday, May 16, 2023 at 8:30am ET, due to scheduling conflicts.

Semler Scientific, Inc., a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, reported financial results for the three months ended March 31, 2023.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, provided an update on recent activity and expected near term milestones across its clinical development pipeline.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the first quarter of 2023 ended March 31, 2023.

INOVIO (NASDAQ:INO) today announced financial results and operational highlights for the first quarter of 2023.